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Summary
Objective: To estimate the efﬁcacy and safety of diacerein as a pain-reducing agent in the treatment of osteoarthritis (OA), using meta-
analysis of published randomized placebo-controlled trials (RCTs).
Methods: Systematic searches of the bibliographic databases Medline, Embase, Cinahl, Chemical Abstracts, Cochrane and Web of Science
for RCTs concerning diacerein treatment of OA. Inclusion criteria: explicit statement about randomization to either diacerein or placebo, and
co-primary outcomes being reduction in pain and improvement in function. Efﬁcacy effect size (ES) was estimated using Hedges’s standard-
ized mean difference. Safety was measured via the risk ratio (RR) of patients having at least one episode of diarrhoea, or withdrawal due to
adverse events. Trials were combined by using random-effects meta-analysis. Consistency was evaluated via the I-squared index.
Results: Six trials (seven sub-studies; 1533 patients) contributed to the meta-analysis, revealing a large degree of inconsistency among the
trials (I 2¼ 56%) in regard to pain reduction: the combined ES was 0.24 [95% conﬁdence intervals (CI): 0.39 to 0.08, P¼ 0.003], favour-
ing diacerein. The statistically signiﬁcant improvement in function (P¼ 0.01) was based on a small amount of heterogeneity (I 2¼ 11%), but
presented a questionable clinical effect size (ES¼0.14). Risk of publication bias could not be excluded, and trials with duration of more than
6 months did not favour diacerein. There was an increased risk of diarrhoea with diacerein (RR¼ 3.51 [2.55e4.83], P< 0.0001), and some
withdrawal from therapy following adverse events (RR¼ 1.58 [1.05e2.36], P¼ 0.03).
Conclusions: Diacerein may be an alternative therapy for OA for patients who cannot take paracetamol or non-steroidal anti-inﬂammatory
drugs (NSAIDs) because of adverse effects or lack of beneﬁt. However, it is associated with increased risk of diarrhoea, and the symptomatic
beneﬁt after 6 months remains unknown.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a common joint disorder and may
occur in any synovial joint in the body, although the condi-
tion is common in hands, knees, hips and spine1. The clin-
ical problems, alongside the pathological and radiographic
changes, include joint pain, short-term morning stiffness,
restricted range of movement, and crepitus2. To manage
symptoms of OA, patients and healthcare providers often
resort to multiple approaches, including lifestyle modiﬁca-
tions, medication, exercise, or surgery3,4. Non-steroidal
anti-inﬂammatory drugs (NSAIDs) are the most commonly
prescribed agents in the management of OA pain, although
they are known to cause serious gastro-intestinal and vas-
cular adverse events5,6 without improving the underlying
structural cartilage damage4. Disease-modifying therapy
would therefore be preferential and beneﬁcial to the*Address correspondence and reprint requests to: Else Marie
Bartels, The Parker Institute, Musculoskeletal Statistics Unit,
Frederiksberg Hospital, DK-2000 F, Denmark. Tel: 45-38164198;
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289patients. Disease-modifying OA drugs (DMOADs) remain
to be developed in order to slow down disease progression
and reduce the patients’ symptoms (i.e., pain and limitations
in daily activities due to poor physical function)7,8.
There is strong evidence of a contribution of additional
pro-inﬂammatory cytokines to cartilage degradation in
OA9e12. One of these is interleukin-1 (IL-1) which stimulates
the degradation process and suppresses cartilage-matrix
synthesis, with the overall result of a severe degradation
of cartilage and following appearance of conditions known
to be characteristic of OA13. A further ﬁnding, which may
increase the deleterious effect of IL-1, is that human OA
cartilage may be more responsive to IL-1 than healthy
cartilage14,15. Diacerein, an anthraquinone derivate, has,
in vitro and in vivo, been shown to inhibit the production
and activity of the cytokine interleukin-1b (IL-1b)16,17. This
will prevent the IL-1b effect of reducing production of carti-
lage-speciﬁc macromolecules. Diacerein will equally dimin-
ish the IL-1b stimulated secretion of metalloproteinases
and aggrecanases, and thereby prevent breakdown of car-
tilage by these enzymes18. A further potential advantage of
using diacerein in OA treatment is, that diacerein does not
290 E. M. Bartels et al.: Symptomatic efﬁcacy and safety of diacerein in the treatment of OAaffect the synthesis of prostaglandins19 and does thereby
not have a deleterious effect on the upper gastro-intestinal
mucosa20. This is an important advantage compared to
NSAID treatment.
There is some evidence that diacerein has both a symp-
tomatic and a structural effect on cartilage, and clinical trials
suggest that diacerein therapy signiﬁcantly decreases
OA symptoms when compared to placebo21. A Cochrane
review, evaluating the efﬁcacy and safety of diacerein in
the treatment of knee and/or hip OA, concludes that diacer-
ein therapy gives a small improvement of pain, but that the
overall effect varies across studies, showing heterogene-
ity22. A divergent result from the Cochrane review is seen
in another meta-analysis of diacerein treatment for OA of
the knee and/or hip23, where a high magnitude of pain relief
is shown, using the Glass score [standardized mean differ-
ence (SMD)] as effect measure. Here, the issue of hetero-
geneity was not addressed23.
As the existing meta-analyses on diacerein do not agree
on magnitude of clinical efﬁcacy, and as the inﬂuence of the
heterogeneity on the effect size (ES) across trials was
not adequately addressed22,23, we decided to revisit the
evidence for diacerein in the treatment of OA. This is espe-
cially important at a time where diacerein may be consid-
ered as a useful DMOAD, and where this may lead to
a better formulation of diacerein with less adverse effects
in the form of diarrhoea.
We performed a systematic review and meta-analysis of
all available randomized placebo-controlled trials (RCTs) to
determine the effects of diacerein on symptomatic efﬁcacy
and safety, and explore whether reported beneﬁcial effects
might be explained by biases affecting individual trials.Materials and methods
Study selection, assessment of eligibility criteria, data extraction, and statis-
tical analysis were performed based on a predeﬁned protocol according to the
Cochrane Collaboration guidelines (http://www.cochrane-handbook.org/).RETRIEVAL OF PUBLISHED STUDIESA thorough and comprehensive literature search for RCTs, all looking at
the efﬁcacy of diacerein therapy for knee and/or hip OA, was carried out
with last search 15th December 2008. The following bibliographic databases
were searched: MEDLINE via PubMed from 1950, EMBASE via OVID from
1980, CINAHL via EBSCO from 1981, Chemical Abstracts via Sciﬁnder from
1907, and Web of Science from 1900, as well as The Cochrane Central Reg-
ister of Controlled Trials, to identify all trials relating diacerein to OA. The
search strategy used a combination of keywords and text words related to
OA. These were combined with various names of the diacerein preparations
(Diacerein, Diacerhein, Rhein, Diacetylrhein, Anthraquinones or Diacetyilr-
hein). We used similar strategies to identify previously published systematic
reviews and meta-analyses3. In addition, we manually searched conference
proceedings for the last 5 years and screened reference lists of all selected
articles, including reviews.INCLUSION AND EXCLUSION CRITERIAWe included randomized, controlled trials of patients with OA of the knee
or hip that compared diacerein treatment with placebo. Two reviewers (EMB,
PKS) independently evaluated reports for eligibility. Disagreements were re-
solved by discussion (HB). No language restrictions applied.QUALITY ASSESSMENT: RISK OF BIASEmpirical studies show that inadequate quality of trials may distort the
results from meta-analyses24. Therefore, inﬂuence of quality of included
studies should be included in meta-analyses25. Two of the reviewers
(EMB, RC) independently assessed (i) randomization followed by conceal-
ment of treatment allocation, (ii) blinding, and (iii) adequacy of statistical anal-
yses (i.e., proper intention-to-treat [ITT] analysis). Randomization andconcealment of allocation was considered adequate if the investigators re-
sponsible for patient selection were unable e prior to allocation e to suspect
which treatment was next. Blinding was considered adequate if participants
and key study personnel ensured complete lack of knowledge of treatment
allocation, and that it was unlikely that the blinding had been broken. Analy-
ses were considered adequate if all randomized patients were analyzed in
the group to which they were randomly allocated, regardless of the treatment
received (ITT principle). Any modified ITT population/analysis would be cat-
egorized as unclear. The assessment of each entry involved answering
a question, with answer ‘A’ indicating low risk of bias (¼adequate handling),
‘B’ indicating unclear (either lack of information or uncertainty concerning the
potential for bias), whereas ‘C’ refers to an inadequate handling of the item
(i.e., high risk of bias per se). Disagreements were resolved by consensus.DATA EXTRACTION AND OUTCOME MEASURESData from the included trials were extracted independently by two
reviewers (PKS and RC). In the case of disagreement, a third reviewer
(EMB) helped to reach a consensus. A standard data-extraction form was
developed for data collection. The following information was systematically
extracted as characteristics of the studies for each of the k randomized trials,
and handled in a customized Microsoft Excel spreadsheet: Demographic
baseline variables, study duration, dosage, attrition, and report of intention-
to-treat analysis. The core-outcome data in each study consisted of the sam-
ple size of the placebo and the experimental group, the number of events in
each group, the values of continuous outcomes, and their SDs at the end of
the study, or the change scores. The pre-speciﬁed primary outcome was
pain reduction. The secondary outcome was disability (including the
Lequesne Impairment Index), while adverse effects were assessed as
reported cases of diarrhoea and the number of withdrawals following any
adverse event. Studies using a 2 2 factorial design were handled as two
mutually independent (sub-) studies, and presented separately in the forest
plots and analyses as based on different patients.STATISTICAL ANALYSISWhenever possible, we used results from the ITT analysis. For the contin-
uous outcomes, pain and disability, we calculated the SMD for each study26
corresponding to Cohen’s d-value27. The corresponding variance (SE2) was
calculated based on the individual study SMD and the number of patients in-
cluded in each group (SE2¼ 1/NEþ 1/NCþSMD2/[2 {NEþNC}])26. As the
unadjusted (Cohen’s) SMD in principle does not treat the variance (SE2) as
an estimate28, we applied (i.e., via multiplication) the Hedges’s bias-correc-
tion (J¼ 1 3/[4 df 1]; i.e., df¼NEþNC 2) by default, adjusting for
small sample bias29. The ESs (i.e., SMDs) were signed so that negative
values (SMD< 0) indicated a beneﬁt of diacerein treatment. The Risk Ratio
(RR) was used as the outcome measure for tolerability and safety, as the RR
is on average more consistent than the Risk Difference, and the alternative
relative effect measure e the odds ratio (OR) e is often misinterpreted30. We
estimated the Number Needed to Treat in order to harm a patient (NNH), with
95% CI on the basis of the combined RR value, applying the overall event
rate in the placebo group as a proxy for baseline risk.
All results are given with 95% CI. We computed homogeneity statistics to
evaluate the agreement of the individual trial results with a ﬁxed-effect meta-
analytic summary31. However, we used standard random-effects meta-anal-
ysis32 as default option, whereas the ﬁxed-effect analysis was applied for
sensitivity analyses. We calculated the I2 statistic33, which describes the per-
centage of total variation across trials that is attributable to heterogeneity
rather than to chance34: I2 values below 25%, from 25% to 50%, and from
50% to 75% correspond to low, moderate, and high between-trial heteroge-
neity, respectively34. We performed a number of pre-speciﬁed sensitivity
analyses: subgroup analyses stratifying the available trials according to
risk of bias, and continuous variables at trial-level were included in pre-spec-
iﬁed REstricted Maximum Likelihood (REML)-based (i.e., random-effects)
meta-regression models35. We performed analyses using SAS software
(version 9.1.3, by SAS Institute Inc., Cary, NC, USA)36,37.ResultsCHARACTERISTICS OF TRIALSFigure 1 shows the selection process of eligible studies
from the ﬁrst recovered references. From the retrieved
166 references, 133 were discarded based on title, abstract,
reference type, being in vitro studies, letters, etc. The
remaining 33 studies were scrutinized for possibility of inclu-
sion and for possible eligible studies given in their reference
lists20e23,38e66. Among these, two papers were excluded as
Fig. 1. Flow chart showing the search strategy and further selection of trials.
291Osteoarthritis and Cartilage Vol. 18, No. 3a consequence of being reviews22,23, and eight for being
reports on other studies (letters, etc.)38e40,42e46. One study
was another part of an included study (The ECHODIAH Co-
hort)41, and ﬁve were excluded as a consequence of using
a non-randomized study design20,47,49e51. Amongst the re-
maining 17 studies, three were excluded due to being dupli-
cates of other published studies48,52,53, six due to not being
placebo-controlled54e59, and two due to being conﬁdential
reports where no response was received when contacting
authors and publishing source65,66. The remaining six
trials21,60e64 were considered eligible for inclusion in the
meta-analysis. Four of these studies were supported fully
or partly by the manufacturer Negma Pharma, France61e64.
In total, the included trials allocated and analyzed 1533
patients (median, 170 [range, 142e493]) to diacerein or
a placebo-control group (Table I). Three trials included
patients with OA of the knee only21,60,61, one trial64 included
patients with OA of the knee or the hip, and two trials62,63
included patients with OA of the hip only. The average
age of the patients was similar across trials, with averages
ranging between 61 years and 65 years (median, 61 years),
and the percentage of women ranged from 55% to 78%
(median, 63%). The study by Nguyen et al.62 used a 2 2
factorial design deﬁning four mutually independent treat-
ment groups [E1] ‘Diacerein’ vs [C1] ‘Placebo’, and [E2]
‘Diacerein & Tenoxicam’ vs [C2] ‘Placebo & Tenoxicam’,
respectively. In the study by Pelletier et al.61, three different
diacerein dosages were compared to the same placebo
group. We included the standard dose (100 mg/day) com-
pared to the placebo group in the meta-analysis. Finally,
the study by Pham et al.60 tested the efﬁcacy/safety of a hy-
aluronic acid compound when compared to either diacerein
or placebo in a masked, double-dummy design.EFFICACYFigure 2(A) shows the ES in pain reduction with diacerein
vs placebo. Pooling the data from the six individual trials
(7 sub-studies), reporting pain as an explicit outcome, pro-
duced a combined ES of 0.24 (95% CI: 0.39 to 0.08,
P¼ 0.003), supporting efﬁcacy of diacerein as opposed toplacebo. The result is based on studies showing a large
amount of heterogeneity (I 2¼ 56.3%). In comparison, the
ﬁxed-effect analysis resulted in a slightly reduced combined
ES of 0.20 (data not shown), possibly indicating some
small-study bias. Figure 2(B) shows the ES in the Lequesne
Index reduction with diacerein vs placebo. Pooling the data
from the seven sub-studies reporting Lequesne produced
a statistically signiﬁcant combined ES of 0.14 (95% CI:
0.25 to 0.03, P¼ 0.010), potentially supporting efﬁcacy
of diacerein treatment compared to placebo. The result is
based on studies showing a small amount of heterogeneity
(I 2¼ 11.4%). Choosing a ﬁxed-effect model instead resulted
in a combined ES of 0.14 (data not shown), indicating ro-
bustness independently of the default model setting, as ex-
pected from the small amount of inconsistency (I 2< 25%).
Table II presents results from stratiﬁed analyses.
Estimates of ESs varied to some degree depending on
adequacy of the concealment of allocation (P¼ 0.21).
Apparently there was no difference between joints when
comparing hip-only with knee-only studies (P¼ 0.60). As
illustrated in Fig. 3, the study duration seemed to be a rele-
vant study-level covariate, enabling a reduction in the
between-study variation, with only studies of no more than
6 months duration showing efﬁcacy. Based on funnel
plots e plotting ESs on the vertical axis against their SEs
on the horizontal axis e resulted in a reduced between-
study variation (t2¼ 0.0153). Therefore, chance is, that
some publication bias is present, i.e. the larger the study
the less pronounced clinical efﬁcacy per se.
Personal information from the investigators of the ECHO-
DIAH study reveals that there is no long-term statistically
signiﬁcant effects of diacerhein (effects measured after
3 years), and that they have no short-term data available.SAFETYEvery healthcare intervention comes with a risk, large or
small, of harmful or adverse effects. As presented in
Fig. 4(A), there was a signiﬁcantly increased risk among pa-
tients allocated to diacerein to have episodes of diarrhoea
when compared to placebo, with a RR¼ 3.51 (95% CI:
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Fig. 2. Efﬁcacy forest plot of trials comparing diacerein with placebo
in OA patients presented as SMDs for (A) pain and (B) disability.
Every square represents the individual study’s effect measure
with 95% CI indicated by horizontal lines. Square sizes are propor-
tional to the precision of the estimate. The overall estimate from the
meta-analysis and its CI are shown at the bottom of each subplot,
represented as a diamond (random-effects model).
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292 E. M. Bartels et al.: Symptomatic efﬁcacy and safety of diacerein in the treatment of OA2.55e4.83, P< 0.0001). Based on the combined risk of
having an incident case of diarrhoea in the placebo group
of 81 (10.4%) among 778 patients, the NNH¼ 4 (95%
CI: 3e7); i.e. one in four patients would have diarrhoea if
diacerein is used instead of placebo. Considering adverse
events in general, Fig. 4(B) shows a slightly increased
risk of withdrawal from diacerein therapy due to adverse
events compared to placebo, with a RR¼ 1.58 (95% CI:
1.05e2.36, P¼ 0.027). With 56 (7.2%) among 778 patients
withdrawing from placebo therapy as a consequence of
adverse events, the NNH was 24 (95% CI: 11e278) for pa-
tients with diacerein; i.e., one in 24 patients would withdraw
because of adverse events related to the use of diacerein.
Thus, based on the empirical evidence, the most important
safety issue associated with use of diacerein will be the in-
creased risk of diarrhoea e which will be expected to occur
in every fourth patient initiating therapy.Discussion
The earlier meta-analyses looking at the efﬁcacy of diac-
erein in OA treatment, do both include the same studies as
included here, except that Rintelen23 only had a congress
abstract available instead of a completed study in one
case21, and Fidelix22 had no access to this. Our patient
Table II
Results of the stratified meta-analyses
Variable Total trials, k ES, SMD (95% CI) t2 I 2 P-value for interaction
All sub-studies 7 0.24 (0.39 to 0.08) 0.023 56.3 e
Concealment of allocation
Adequate 6 0.20 (0.35 to 0.04) 0.019 46.0 0.21
Unclear 1 0.47 (0.87 to 0.07)
Patient blinding
Adequate 5 0.24 (0.44 to 0.05) 0.030 73.3 0.93
Unclear 2 0.23 (0.54 to 0.09)
Intention-to-treat analysis
Adequate 3 0.18 (0.44 to 0.09) 0.028 69.6 0.56
Unclear 4 0.28 (0.48 to 0.07)
Affected joint
Hip 3 0.16 (0.38 to 0.07) 0.022 53.8 0.60
Knee 3 0.24 (0.48 to 0.01)
k¼ number of sub-studies (data points). t2¼ Tau-squared (between-study variance); I 2¼ inconsistency index (measuring heterogeneity).
293Osteoarthritis and Cartilage Vol. 18, No. 3material is in this respect larger than in the Fidelix analy-
sis22. Rintelen did though have access to two unpublished
reports which we, despite of several attempts, have not
been able to get access to. The patient number is therefore-0.45
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Fig. 3. ESs as a function of study duration. ESs on the vertical axis
are plotted against the study duration on the horizontal axis. Size of
every circle is proportional to the precision of each efﬁcacy esti-
mate. The solid line indicates the predicted treatment magnitude
and direction; using an REML-based model.higher in Rintelen’s study, but we do consider these reports
with some suspicion, since they suddenly seems to be man-
ufacturer’s secret. The extra included studies in the two
meta-analyses were all concerned with a comparison of di-
acerein with other treatment, mainly NSAIDs, and this is
outside our aim with this work, since we wish to see, if diac-
erein could be a valid alternative to others. The focus in the
present study was in that respect slightly different from the.0
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Fig. 4. Safety forest plot of trials comparing diacerein with placebo
in OA patients presented as RR’s for (A) diarrhea and (B) with-
drawal due to any adverse events. Every square represents the in-
dividual study’s effect measure with 95% CI indicated by horizontal
lines. Square sizes are proportional to the precision of the estimate.
The overall estimate from the meta-analysis and its CI are shown at
the bottom of each subplot, represented as a diamond (random-
effects model).
294 E. M. Bartels et al.: Symptomatic efﬁcacy and safety of diacerein in the treatment of OAearlier meta-analyses, where we wished to look at diacerein
as a suitable drug in its own right.
The main result of our analysis was the ﬁnding of a small
efﬁcacy of diacerein therapy for OA, showing a small reduc-
tion of pain in accordance with both of the earlier meta-anal-
ysis22,23. When exploring the observed heterogeneity, it
was evident that efﬁcacy was only present in the trials
with less than 6 months duration. For trials with more than
6 months of therapy, diacerein intake did not show a signif-
icant effect on pain reduction. In the present analysis of
diacerein, the analysis of heterogeneity between studies
showed some inconsistency. Based on modiﬁed funnel
plots, one may conclude that chance is that some publica-
tion bias is present, i.e., the larger the study the less pro-
nounced clinical efﬁcacy per se. It is anticipated that only
with more large-scale trials will we be able to answer
what the true efﬁcacy of diacerein in pain therapy is. Diac-
erein intake did not result in an improvement of physical
function in trials with more than 6 months of treatment.
This outcome did not have the same problem with heteroge-
neity between studies as seen for the pain outcome. The re-
sult is in accordance with Rintelen23, but not with Fidelix22,
and one may speculate if the larger patient number has
helped to show this very small effect. Whether diacerein
has a longer-term effect (>6 months) for pain and physical
function is worth considering in further investigations.
Tolerability assessments revealed the superiority of pla-
cebo over diacerein concerning diarrhoea, an adverse
effect noticed in all six included studies21,60e64. It is worth
mentioning though, that none of the studies attempted to
characterize or grade the loose stools reported (frequency,
watery/formed, severity, etc.). The diarrhoea caused by
diacerein intake could be linked to IL-1b inhibition. IL-1b is
known to increase at the beginning of dysentery in pigs67
and in Escherichia coli caused diarrhoea68, and increased
IL-1b is also seen in connection with irritable bowel syn-
drome69. The cytokine is thought to be part of the system
triggering immune responses towards infections in the
gut68. An inhibition of IL-1b may therefore make the diacer-
ein-treated individual less able to ﬁght off common gut infec-
tions, giving the higher incidence of diarrhoea observed in
the diacerein group, when compared to the placebo group.
There is though, no description of the severity of the diar-
rhoea in the studies, and it is therefore not possible to as-
sess, if some diacerein drug types are more likely to give
a milder form and therefore be more tolerable for the
patients.
OA is the most common type of arthritis in older
adults70,71 with up to 40% of those aged over 65 showing
symptomatic knee or hip OA3. If diacerein with its preferen-
tial risk/beneﬁt ratio had the potential of being as efﬁcient in
pain treatment as NSAIDs, it would be an important alterna-
tive for people who are contraindicative to NSAIDs. Like ef-
fects of other therapies applied in OA72,73, the effect of
diacerein may wear off after some time. The reason for
the time-dependent effect remains unknown. Whether this
is related to the non-speciﬁc treatment effects4, a narrow
therapeutic window, or OA per se, have yet to be
determined.
Diacerein does give an increased risk of experiencing di-
arrhoea, with one in four suffering this inconvenience. With
a risk of various more severe adverse effects of NSAIDs, in-
cluding cardiovascular, severe gastro-intestinal, hepatotox-
icity, and nephrotoxicity events, as well as rare events of
adverse effects on the central nervous system74. Diacerein
may be more suitable for the elderly patients, or people at
high risk of GI bleeding and cardiovascular co-morbidities.Diacerein may have symptom-modifying effects in OA.
However, it causes diarrhoea. Diacerein may be recom-
mended as an alternative therapy to NSAIDs, especially
for people at high risk of GI bleeding and cardiovascular
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